- Trials with a EudraCT protocol (660)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
660 result(s) found for: covid-19.
Displaying page 1 of 33.
EudraCT Number: 2020-002871-36 | Sponsor Protocol Number: VIR-7831-5001 | Start Date*: 2020-11-27 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) i... | ||||||||||||||||||
Medical condition: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003690-21 | Sponsor Protocol Number: R10933-10987-COV-2067 | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19 | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002641-42 | Sponsor Protocol Number: C4591001 | Start Date*: 2020-09-04 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002537-15 | Sponsor Protocol Number: R10933-10987-COV-2066 | Start Date*: 2020-10-06 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2024-000001-33 | Sponsor Protocol Number: C4591048 | Start Date*: 2024-02-07 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005442-42 | Sponsor Protocol Number: C4591007 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A S... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000714-33 | Sponsor Protocol Number: PT26/17/01 | Start Date*: 2023-02-21 | |||||||||||
Sponsor Name:tiakis Biotech AG (formerly Proteo Biotech AG) | |||||||||||||
Full Title: Efficacy and safety of Tiprelestat for treatment of severe COVID-19 (COMCOVID trial) | |||||||||||||
Medical condition: Adult patients with COVID-19 fulfilling the following criteria: -First laboratory-confirmation of the current episode of SARS-CoV-2 infection (COVID-19) as determined by PCR or antigen test (no sel... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000454-26 | Sponsor Protocol Number: 76702 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Establishing the safety, tolerability and immunogenicity of intradermal delivery of mRNA SARS-CoV-2 vaccine in healthy adults | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001546-19 | Sponsor Protocol Number: ARGX-117-2001 | Start Date*: 2020-04-21 |
Sponsor Name:argenx BV | ||
Full Title: A First-in-Human Study in Adult Subjects Hospitalized with Covid-19 to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of ARGX-117 | ||
Medical condition: PCR-confirmed Covid-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001749-38 | Sponsor Protocol Number: IL2-COVID | Start Date*: 2020-10-02 |
Sponsor Name:Azienda Ospedaliero-Universitaria S. Andrea | ||
Full Title: PET/CT with 68Ga-IL2 for imaging IL2R+ cells in COVID-19+ patients | ||
Medical condition: Evaluation of the inflammatory infiltrate in patients with COVID-19 in order to map the "trafficking" of T-activated lymphocytes and clarify the causes of lymphopenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001022-22 | Sponsor Protocol Number: COV-2-STs | Start Date*: 2021-05-14 |
Sponsor Name:Γενικό Νοσοκομείο Θεσσαλονίκης "Γεώργιος Παπανικολάου" | ||
Full Title: Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients | ||
Medical condition: COVID-19 high-risk patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005299-36 | Sponsor Protocol Number: EXEVIR0101 | Start Date*: 2021-04-21 | |||||||||||
Sponsor Name:ExeVir Bio BV | |||||||||||||
Full Title: A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Effica... | |||||||||||||
Medical condition: Subjects hospitalised for COVID 19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003240-25 | Sponsor Protocol Number: FIBHGM-ECNC003-2021 | Start Date*: 2023-06-01 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Gregorio Marañón | ||
Full Title: PHASE I/IIa OPEN CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ALLOGENIC ADMINISTRATION OF TREG CELLS OBTAINED FROM THYMAL TISSUE (thyTreg) IN THE CONTROL OF IMMUNOLOGICAL HYPERACTIVATION ... | ||
Medical condition: immune hyperactivation in COVID-19 patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000167-69 | Sponsor Protocol Number: AIC649-02-II-01 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:AiCuris Anti-Infective Cures AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ... | |||||||||||||
Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000864-32 | Sponsor Protocol Number: NL76798.078.21 | Start Date*: 2021-03-29 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulines | |||||||||||||
Medical condition: COVID-19 or protective effect against in B-cell depleted patients or vaccination non-responders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000417-16 | Sponsor Protocol Number: Uni-Köln-4480 | Start Date*: 2021-10-20 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 | |||||||||||||
Medical condition: Patients who are tested positive for SARS-CoV-2 by PCR from upper or lower respiratory sites and are at increased risk for developing critical disease presenting with moderate disease -WHO ordinal ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001364-29 | Sponsor Protocol Number: AdiQure/COVID-19 | Start Date*: 2020-04-20 | |||||||||||||||||||||
Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud | |||||||||||||||||||||||
Full Title: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia | |||||||||||||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002982-33 | Sponsor Protocol Number: 2020-PDNO-002 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Attgeno AB | |||||||||||||
Full Title: An open-label, multicenter study to evaluate the efficacy, safety and tolerability of PDNO (nitrosooxypropanol) infusion in COVID-19 patients with acute pulmonary hypertension | |||||||||||||
Medical condition: Acute pulmonary hypertension during COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000548-23 | Sponsor Protocol Number: UKE-SARS-COV-2-ST | Start Date*: 2021-07-07 |
Sponsor Name:University Medical Center Hamburg-Eppendorf | ||
Full Title: A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults | ||
Medical condition: This study is designed to evaluate the safety, tolerability and reactogenicity of intramuscular dose administrations of: -3 dose levels of the MVA-SARS-2-ST vaccine in healthy SARS-CoV-2 seronegati... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001555-14 | Sponsor Protocol Number: NBK272/1/2021 | Start Date*: 2023-01-05 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases | ||
Medical condition: fibrotic interstitial lung disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.